At the moment clinicians make life or death decisions about patients in Intensive Care Units (ICU) based on very limited continuous clinical data (heart rate, blood pressure, etc). Clinicians do not have continuous data on key blood analytes such as: glucose, lactate, and dozens of others analytes and are therefore making decisions based on poor data. Nor do clinicians have data on how patients are reacting to drugs that are being administered (especially toxic drugs like anti-biotics, chemotherapeutics and immunosuppressants). Studies show that tight glucose monitoring alone can reduce death rates in ICU by up to 40% and also significantly reduce healthcare costs.

How they’re disrupting

Probe Scientific is working with leading clinical care specialists and researchers to bring continuous and automated real-time blood monitoring into routine practise. Studies are currently underway across Europe with a number of analytes from glucose, to lactate to immunosuppressants and anti-biotics – all demonstrating that by continuously tracking analytes or drugs in blood patient outcomes are significantly improved.

Disruption potential

Transformation of healthcare from reactive to proactive with the potential to save millions of lives.

Investments and future

Probe Scientific has raised circa $6m to date from private investors and two institutional investors: Catapult and NESTA. Probe Scientific have also signed deals with a major Italian pharma company and a Japanese pharma company which have brought in nearly $3m. In 2015 Probe achieved a small operating profit and Probe is well placed to transform not only healthcare monitoring in ICU but the platform technology also has multiple other applications from neonate monitoring, to drug delivery and sports science. Probe Scientific is currently raising additional funding to accelerate development with a view to an IPO in 2017.